Booster response to 30 μg adjuvanted clade 2/ Indonesia/5/05-RG2 vaccine at 22 months following the first vaccination.

<p>Booster response to 30 μg adjuvanted clade 2/ Indonesia/5/05-RG2 vaccine at 22 months following the first vaccination.</p

Antibody persistence as defined by HI antibody titer at 6/15/22-months following the first vaccination with clade 1 A/Vietnam/1194/2004/NIBERG-14.

<p>Antibody persistence as defined by HI antibody titer at 6/15/22-months following the first vaccination with clade 1 A/Vietnam/1194/2004/NIBERG-14.</p

Solicited adverse events following booster vaccination or in case of clade 2 primary vaccination within 3 to 7-days after vaccination.

<p>Solicited adverse events following booster vaccination or in case of clade 2 primary vaccination within 3 to 7-days after vaccination.</p

21 Day Booster response to 7.5 μg clade 1 A/Vietnam/1194/2004/NIBERG-14 6-months after the first vaccination.

<p>21 Day Booster response to 7.5 μg clade 1 A/Vietnam/1194/2004/NIBERG-14 6-months after the first vaccination.</p

Primary response following clade 2 A/Indonesia /5/05-RG2 as determined by HIH method.

<p>Primary response following clade 2 A/Indonesia /5/05-RG2 as determined by HIH method.</p